Biologics in the Treatment of Lupus Erythematosus: A Critical Literature Review
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Biologics in the Treatment of Lupus Erythematosus: A Critical Literature Review
Authors
Keywords
-
Journal
Biomed Research International
Volume 2019, Issue -, Pages 1-17
Publisher
Hindawi Limited
Online
2019-07-19
DOI
10.1155/2019/8142368
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The NET-effect of combining rituximab with belimumab in severe systemic lupus erythematosus
- (2018) Tineke Kraaij et al. JOURNAL OF AUTOIMMUNITY
- Ofatumumab for B cell depletion in patients with systemic lupus erythematosus who are allergic to rituximab
- (2018) Sherry Masoud et al. RHEUMATOLOGY
- Efficacy and Safety of Atacicept in Patients With Systemic Lupus Erythematosus
- (2018) Joan T. Merrill et al. Arthritis & Rheumatology
- Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial
- (2018) Joan T Merrill et al. ANNALS OF THE RHEUMATIC DISEASES
- Adverse Reactions to Biologic Therapy
- (2017) Sheenal V. Patel et al. IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA
- Biotherapies in systemic lupus erythematosus: New targets
- (2017) Estibaliz Lazaro et al. JOINT BONE SPINE
- Comparative efficacy and safety of intravenous or subcutaneous belimumab in combination with standard therapy in patients with active systemic lupus erythematosus: a Bayesian network meta-analysis of randomized controlled trials
- (2017) Y H Lee et al. LUPUS
- Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
- (2017) Xavier Montalban et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combination therapy of rituximab and mycophenolate mofetil in childhood lupus nephritis
- (2017) Julien Hogan et al. PEDIATRIC NEPHROLOGY
- Obinutuzumab induces superior B-cell cytotoxicity to rituximab in rheumatoid arthritis and systemic lupus erythematosus patient samples
- (2017) Venkat Reddy et al. RHEUMATOLOGY
- Expanding the therapeutic options for renal involvement in lupus: eculizumab, available evidence
- (2017) Savino Sciascia et al. RHEUMATOLOGY INTERNATIONAL
- Spotlight on blisibimod and its potential in the treatment of systemic lupus erythematosus: evidence to date
- (2017) Aleksander Lenert et al. Drug Design Development and Therapy
- Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double-Blind, Placebo-Controlled Trials
- (2017) Megan E. B. Clowse et al. Arthritis & Rheumatology
- Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus
- (2017) Richard Furie et al. Arthritis & Rheumatology
- Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty-Two-Week Randomized, Double-Blind, Placebo-Controlled Study
- (2017) William Stohl et al. Arthritis & Rheumatology
- Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study
- (2016) Munther Khamashta et al. ANNALS OF THE RHEUMATIC DISEASES
- Restoring regulation – IL-2 therapy in systemic lupus erythematosus
- (2016) Jens Y. Humrich et al. Expert Review of Clinical Immunology
- A critical review of clinical trials in systemic lupus erythematosus
- (2016) M A Mahieu et al. LUPUS
- Successful treatment of life-threatening autoimmune haemolytic anaemia with ofatumumab in a patient with systemic lupus erythematosus
- (2016) Theofanis Karageorgas et al. RHEUMATOLOGY
- Long-Term Safety and Efficacy of Epratuzumab in the Treatment of Moderate-to- Severe Systemic Lupus Erythematosus: Results From an Open-Label Extension Study
- (2016) D. J. Wallace et al. ARTHRITIS CARE & RESEARCH
- Post Hoc Analysis of the Phase II/III APRIL-SLE Study: Association Between Response to Atacicept and Serum Biomarkers Including BLyS and APRIL
- (2016) Caroline Gordon et al. Arthritis & Rheumatology
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Treatment With Sirukumab (CNTO 136) in Patients With Active Lupus Nephritis
- (2016) Brad H. Rovin et al. Arthritis & Rheumatology
- Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study
- (2015) J T Merrill et al. ANNALS OF THE RHEUMATIC DISEASES
- A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-α) in patients with systemic lupus erythematosus (ROSE)
- (2015) Kenneth C Kalunian et al. ANNALS OF THE RHEUMATIC DISEASES
- Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study
- (2015) D A Isenberg et al. ANNALS OF THE RHEUMATIC DISEASES
- The mechanistic impact of CD22 engagement with epratuzumab on B cell function: Implications for the treatment of systemic lupus erythematosus
- (2015) Thomas Dörner et al. AUTOIMMUNITY REVIEWS
- Safety and Efficacy of Belimumab to Treat Systemic Lupus Erythematosus in Academic Clinical Practices
- (2015) J. S. Hui-Yuen et al. JOURNAL OF RHEUMATOLOGY
- Molecular basis for antagonistic activity of anifrolumab, an anti-interferon–α receptor 1 antibody
- (2015) Li Peng et al. mAbs
- A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study
- (2014) R A Furie et al. ANNALS OF THE RHEUMATIC DISEASES
- Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial)
- (2014) David Isenberg et al. ANNALS OF THE RHEUMATIC DISEASES
- Emerging biological therapies for systemic lupus erythematosus
- (2014) Chi Chiu Mok EXPERT OPINION ON EMERGING DRUGS
- Current role of rituximab in systemic lupus erythematosus
- (2014) Chi Chiu Mok International Journal of Rheumatic Diseases
- Type I Interferon in the Pathogenesis of Lupus
- (2014) M. K. Crow JOURNAL OF IMMUNOLOGY
- When biologics should be used in systemic lupus erythematosus?
- (2014) Jacques-Eric Gottenberg et al. PRESSE MEDICALE
- Ofatumumab: a novel treatment for severe systemic lupus erythematosus
- (2014) C. C. Thornton et al. RHEUMATOLOGY
- Belimumab for the Treatment of Systemic Lupus Erythematosus (Sle) In Greece: A Cost-Effectiveness and Cost-Utility Analysis
- (2014) K. Athanasakis et al. VALUE IN HEALTH
- Health Technology Assessment of Belimumab: A New Monoclonal Antibody for the Treatment of Systemic Lupus Erythematosus
- (2014) Maria Lucia Specchia et al. Biomed Research International
- Treatment of Lupus Nephritis With Abatacept: The Abatacept and Cyclophosphamide Combination Efficacy and Safety Study
- (2014) Arthritis & Rheumatology
- Improvements in health-related quality of life with belimumab, a B-lymphocyte stimulator-specific inhibitor, in patients with autoantibody-positive systemic lupus erythematosus from the randomised controlled BLISS trials
- (2013) Vibeke Strand et al. ANNALS OF THE RHEUMATIC DISEASES
- Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study
- (2013) Daniel J Wallace et al. ANNALS OF THE RHEUMATIC DISEASES
- Comparison of Alternative Primary Outcome Measures for Use in Lupus Nephritis Clinical Trials
- (2013) David Wofsy et al. ARTHRITIS AND RHEUMATISM
- Efficacy and Safety of Ocrelizumab in Active Proliferative Lupus Nephritis: Results From a Randomized, Double-Blind, Phase III Study
- (2013) Eduardo F. Mysler et al. ARTHRITIS AND RHEUMATISM
- Sifalimumab, a Human Anti-Interferon-α Monoclonal Antibody, in Systemic Lupus Erythematosus: A Phase I Randomized, Controlled, Dose-Escalation Study
- (2013) Michelle Petri et al. ARTHRITIS AND RHEUMATISM
- Trogocytosis of multiple B-cell surface markers by CD22 targeting with epratuzumab
- (2013) E. A. Rossi et al. BLOOD
- Targeting the complement system in systemic lupus erythematosus and other diseases
- (2013) Maria-Louise Barilla-LaBarca et al. CLINICAL IMMUNOLOGY
- Clinical outcomes and safety of rituximab treatment for patients with systemic lupus erythematosus (SLE) – results from a nationwide cohort in Germany (GRAID)
- (2013) M Witt et al. LUPUS
- Epratuzumab for Systemic Lupus Erythematosus
- (2013) DJ Wallace et al. LUPUS
- Belimumab for Systemic Lupus Erythematosus
- (2013) Bevra Hannahs Hahn NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and Safety of Abatacept in Lupus Nephritis: A Twelve-Month, Randomized, Double-Blind Study
- (2013) Richard Furie et al. Arthritis & Rheumatology
- Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials
- (2012) Susan Manzi et al. ANNALS OF THE RHEUMATIC DISEASES
- Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: Results of a phase I, placebo-controlled, double-blind, dose-escalation study
- (2012) Jacqueline M. McBride et al. ARTHRITIS AND RHEUMATISM
- Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus
- (2012) William Stohl et al. ARTHRITIS AND RHEUMATISM
- Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The lupus nephritis assessment with rituximab study
- (2012) Brad H. Rovin et al. ARTHRITIS AND RHEUMATISM
- Emerging therapies for systemic lupus erythematosus — Focus on targeting interferon-alpha
- (2012) Eben I. Lichtman et al. CLINICAL IMMUNOLOGY
- Abatacept for systemic lupus erythematosus: the outlook
- (2012) Chi Chiu Mok EXPERT OPINION ON BIOLOGICAL THERAPY
- Multicenter longitudinal study of B-lymphocyte depletion in refractory systemic lupus erythematosus: the LESIMAB study
- (2012) A Fernández-Nebro et al. LUPUS
- Optimization of current and future therapy for autoimmune diseases
- (2012) Lawrence Steinman et al. NATURE MEDICINE
- Safety profile and clinical activity of sifalimumab, a fully human anti-interferon monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study
- (2011) J. T. Merrill et al. ANNALS OF THE RHEUMATIC DISEASES
- B cell biomarkers of rituximab responses in systemic lupus erythematosus
- (2011) Edward M. Vital et al. ARTHRITIS AND RHEUMATISM
- A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus
- (2011) Richard Furie et al. ARTHRITIS AND RHEUMATISM
- Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: Pooled data from European cohorts
- (2011) Cándido Díaz-Lagares et al. AUTOIMMUNITY REVIEWS
- Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies
- (2011) G. Niederfellner et al. BLOOD
- Targeting BLyS in rheumatic disease: the sometimes-bumpy road from bench to bedside
- (2011) William Stohl et al. CURRENT OPINION IN RHEUMATOLOGY
- Type I Interferon and Systemic Lupus Erythematosus
- (2011) Keith B. Elkon et al. JOURNAL OF INTERFERON AND CYTOKINE RESEARCH
- Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial
- (2011) Sandra V Navarra et al. LANCET
- The type I interferon system in the development of lupus
- (2011) Lars Rönnblom et al. SEMINARS IN IMMUNOLOGY
- EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs
- (2010) G. K. Bertsias et al. ANNALS OF THE RHEUMATIC DISEASES
- Unanswered questions in evaluating rituximab efficacy: Comment on the article by Merrill et al
- (2010) Lidia Rudnicka et al. ARTHRITIS AND RHEUMATISM
- The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: Results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial
- (2010) J. T. Merrill et al. ARTHRITIS AND RHEUMATISM
- Ofatumumab, a human anti-CD20 monoclonal antibody, for treatment of rheumatoid arthritis with an inadequate response to one or more disease-modifying antirheumatic drugs: Results of a randomized, double-blind, placebo-controlled, phase I/II study
- (2010) Mikkel Østergaard et al. ARTHRITIS AND RHEUMATISM
- Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry
- (2010) J.-E. Gottenberg et al. ARTHRITIS AND RHEUMATISM
- Safety and efficacy of rituximab in systemic lupus erythematosus: Results from 136 patients from the French autoimmunity and rituximab registry
- (2010) Benjamin Terrier et al. ARTHRITIS AND RHEUMATISM
- Tocilizumab in systemic lupus erythematosus: Data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study
- (2010) Gabor G. Illei et al. ARTHRITIS AND RHEUMATISM
- Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia
- (2010) William G. Wierda et al. JOURNAL OF CLINICAL ONCOLOGY
- Interferon-regulated chemokines as biomarkers of systemic lupus erythematosus disease activity: A validation study
- (2009) Jason W. Bauer et al. ARTHRITIS AND RHEUMATISM
- A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus
- (2009) Daniel J. Wallace et al. ARTHRITIS AND RHEUMATISM
- Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: The randomized, double-blind, phase ii/iii systemic lupus erythematosus evaluation of rituximab trial
- (2009) Joan T. Merrill et al. ARTHRITIS AND RHEUMATISM
- Abetimus sodium: a medication for the prevention of lupus nephritis flares
- (2009) Diane M Horowitz et al. EXPERT OPINION ON PHARMACOTHERAPY
- A Low Interleukin-2 Receptor Signaling Threshold Supports the Development and Homeostasis of T Regulatory Cells
- (2009) Aixin Yu et al. IMMUNITY
- The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus
- (2009) Michael P. Cancro et al. JOURNAL OF CLINICAL INVESTIGATION
- CTLA4Ig Alters the Course of Autoimmune Disease Development in Lyn-/- Mice
- (2009) S. A. Oracki et al. JOURNAL OF IMMUNOLOGY
- Efficacy and safety of infliximab in active SLE: a pilot study
- (2009) SS Uppal et al. LUPUS
- Rituximab in systemic lupus erythematosusA systematic review of off-label use in 188 cases
- (2009) M Ramos-Casals et al. LUPUS
- Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus
- (2008) D Albert et al. ANNALS OF THE RHEUMATIC DISEASES
- Abetimus sodium for renal flare in systemic lupus erythematosus: Results of a randomized, controlled phase III trial
- (2008) Mario H. Cardiel et al. ARTHRITIS AND RHEUMATISM
- Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus
- (2008) Richard Furie et al. ARTHRITIS RESEARCH & THERAPY
- Association of a gene expression profile from whole blood with disease activity in systemic lupus erythaematosus
- (2007) M Nikpour et al. ANNALS OF THE RHEUMATIC DISEASES
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started